This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Overlooked Drug Stocks to Watch Out for in 2017
by Arpita Dutt
As we start the New Year, here is a look at 3 drug stocks that have not been in the news much but have been witnessing upward estimate revisions and sport a strong Zacks Rank.
Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist
by Zacks Equity Research
On Dec 29, 2016, we issued an updated research report on Zoetis Inc. (ZTS).
Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife
by Zacks Equity Research
Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife
5 Profitable Stocks to Buy for Great Returns
by Zacks Equity Research
Net income ratio gives us the exact profit level of a company and reflects the percentage of net income to total sales revenue.
Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
by Zacks Equity Research
Shares of Portola (PTLA) surged 33.8% after the FDA granted priority review to anticoagulant, betrixaban. Betrixaban was also accepted by the EMA for review.
4 Top Stocks with Earnings Acceleration to Buy in 2017
by Tirthankar Chakraborty
These stocks have witnessed increase in quarter-over-quarter earnings growth within a stipulated frame of time.
Ironwood, Allergan Report Positive Linzess IBS-C Study Data
by Zacks Equity Research
Ironwood (IRWD) and Allergan (AGN) report phase IIb study data on colonic release formulations of Linzess for the treatment of irritable bowel syndrome with constipation.
Sarepta's (SRPT) Application for DMD Drug Accepted in the EU
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization application (MAA) for Exondys 51.
Agios Stops Development of PKR Activator AG-519, Stock Falls
by Zacks Equity Research
Shares of Agios (AGIO) tanked 19.4% after the company decided to discontinue the development of its PKR activator, AG-519.
Roche (RHHBY) to Terminate Pacifica Bioscience Agreement
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.
Trovagene to Focus More on Liquid Biopsy Testing Market
by Zacks Equity Research
Trovagene, Inc. (TROV), recently announced that it will increase its focus on the global distribution of kits and systems to clinical research laboratories for the liquid biopsy oncology testing market.
athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017
by Zacks Equity Research
athenahealth Inc. (ATHN) reaffirmed its full-year 2016 guidance and issued a stable guidance for 2017.
Intuitive Surgical (ISRG) Raises Share Buyback to $3 Billion
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) increased the authorized amount available under the company's share repurchase program to $3.0 billion.
Envision Healthcare Acquires Desert Mountain Consultants
by Zacks Equity Research
Envision Healthcare Corporation (EVHC), a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced the acquisition of Desert Mountain Consultants in Anesthesia, Inc.
Eli Lilly (LLY) to Offer Discount on Insulin from January
by Zacks Equity Research
Eli Lilly (LLY) announced that the company will offer access to its insulin products at discounted prices, starting Jan 2017.
Kite Pharma Enters into Partnership with Vitruvian Networks
by Zacks Equity Research
Kite Pharma (KITE) entered into a strategic partnership with Vitruvian Networks to create a software solution to support commercial availability of T-cell therapies.
Proteon Slips to 52-Week Low on Kidney Disease Study Data
by Zacks Equity Research
Proteon's (PRTO) shares hit a 52-week low after reporting poor top-line phase III data on vonapanitase in patients with chronic kidney disease.
Repros to Meet with the FDA for Phase III Proellex Program
by Zacks Equity Research
Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.
Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval
by Zacks Equity Research
Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.
Corcept Korlym Positive in Phase I/II Breast Cancer Study
by Zacks Equity Research
Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.
Novartis Offers Positive Data on Breast Cancer Drug LEE011
by Zacks Equity Research
Novartis (NVS) announced results from the phase III MONALEESA-2 study on LEE011 for the treatment of first-line HR+/HER2- advanced breast cancer.
Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails
by Zacks Equity Research
Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.
Endo (ENDP) Inks Deal to Return Belbuca Rights to BioDelivery
by Zacks Equity Research
Endo (ENDP) announced that it has entered into an agreement to return the rights for Belbuca to BioDelivery (BDSI).
Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK
by Zacks Equity Research
Pfizer (PFE) fined for hiking price of an anti-epilepsy drug by up to 2,600% by the Competition and Markets Authority of the UK.
Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, Citrix Systems, VMware and Sanchez Energy
by Zacks Equity Research
Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, Citrix Systems, VMware and Sanchez Energy